By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Pharma R & D Spending is Down
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Pharma R & D Spending is Down
BusinessHealth Reform

Pharma R & D Spending is Down

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

And that’s probably bad news. Here is Megan McArdle, writing in The Atlantic:

For the first time ever last year, the global drug industry cut its R&D spending.  The trend is expected to continue, at least in the near term.

And that’s probably bad news. Here is Megan McArdle, writing in The Atlantic:

For the first time ever last year, the global drug industry cut its R&D spending.  The trend is expected to continue, at least in the near term.

More Read

millennials.jpg
Why Healthcare Marketers Shouldn’t Only Be Targeting Millennial Patients Online
Did We Learn the Secret to Fixing Healthcare in Kindergarten?
Juliette Kayyem, MA Gubernatorial Candidate, Speaks with the Health Business Blog
Psychiatrists Now Working Online: How the Mental Healthcare Industry Is Evolving
Healthcare Companies Are Now Technology Companies?

You might initially think that this is good news for cost control–the expensive brand name drugs will all go generic, and we’ll save a bunch of money on prescription drugs.  And indeed, this is absolutely true.  But this will have repercussions for other areas of health care, and those repercussions are not good.  While some drugs are simply an added expense (think chemotherapy prolonging the lives of people who would otherwise have died sooner), many of the real blockbusters substitute for labor-intensive treatment.  Statins instead of cardiac catheterizations or coronary bypasses.  Avandia instead of amputations.  Hydro-chlorothiazide instead of nursing home care for your massive stroke.

We’ll still have all those drugs, of course.  But with less R&D, we’ll presumably see fewer pharmaceutical substitutes for the expensive conditions we still spend a lot of money treating, like Alzheimer’s. Which means that health care expenses might actually rise faster than we expect.

   

TAGGED:healthcare businesshealthcare reformpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025

You Might also Like

Your Employees are Depressed. Why Employers and You Should Care

November 12, 2012

Preventable Readmissions and a Recent OIG Advisory Opinion

August 27, 2013

Free Health Care

June 15, 2011

Health Care Buzz Today

August 10, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?